Pharmaco-genomic mutation labeling

• US 8,606,526 B1
• Filed: 08/13/2009
• Issued: 12/10/2013
• Est. Priority Date: 10/18/2002
• Status: Expired due to Fees

• Current Assignee: Antonia Teresita Ancheta Maninang, Dennis Sunga Fernandez
• Original Assignee: Antonia Teresita Ancheta Maninang, Dennis Sunga Fernandez
• Inventors: Fernandez, Dennis Sunga, Maninang, Antonia Teresita Ancheta
• Primary Examiner(s): ZEMAN, MARY K
• Application Number:
  US12/541,146
• Time in Patent Office: 1,580 Days
• Field of Search: None
• US Class Current: 702/19
• CPC Class Codes: G16B 20/00 ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• CPC Class Codes: G16B 20/20 Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• CPC Class Codes: G16B 30/00 ICT specially adapted for sequence analysis involving nucleotides or amino acids
• CPC Class Codes: G16B 5/00 ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• CPC Class Codes: G16B 5/20 Probabilistic models
• CPC Class Codes: G16B 99/00 Subject matter not provided for in other groups of this subclass
• CPC Class Codes: G16H 10/20 for electronic clinical trials or questionnaires
• CPC Class Codes: G16H 70/20 relating to practices or guidelines
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Electronic label processor compares bioinformatic values to determine pharmaco-genomic mutation associated with host. Label display indicates pharmaco-genomic mutation, which is network-accessible for modified medical message. Bioinformatic values are determined preferably at different times.

Claims

1. Bio-sensor and electronic label based apparatus for integrated genomic, proteomic and metabolomic sensing to automate host pharmacokinetic or clinical analysis comprising:

bio-sensor for sensing a host genomic value, a host proteomic value, and a host metabolomic value associated with a GPCR condition;

electronic label processor coupled to the bio-sensor for comparing electronically a first bioinformatic value with the host genomic value to determine one or more genomic mutant or variant associated with the host, a second bioinformatic value with the host proteomic value to determine one or more proteomic mutant or variant associated with the host, and a third bioinformatic value with the host metabolomic value to determine one or more metabolomic mutant or variant associated with the host; and

display coupled to the electronic label processor for alerting electronically a physician, nurse, hospital, pharmacy, paramedic or other professional medical staff a pharmacokinetic or clinical indication based upon the compared first, second and third bioinformatic values to alert such staff one or more determined host genomic, proteomic or metabolomic mutant or variant association with such host susceptibility or predisposition to toxicity or adverse reaction to side effect to identified food, drug or medical treatment;

wherein the bio-sensor senses the host genomic value, the host proteomic value, and the host metabolomic value associated with the GPCR condition according to integrated chip refractive-index micro-interferometry detection using coherent VCSEL, laser diode, or He—

Ne laser source, etched substrate capillary channel for sample reception and analysis, and reflected laser-light reflection photodetector, said bio-sensor further senses the host genomic value, the host proteomic value, and the host metabolomic value associated with the GPCR condition using optical evanescent wave detector using flow-based surface plasmon resonance in micro-fabricated integrated fluidic cartridge to capture tagged proteins, thiol coupling, or coil-coil interaction, wherein resonance angle is continuously monitored to detect changes in refractive resonance angle and refractive index corresponding to changes in mass when certain ligand binds to, or dissociates from, immobilized binding partner, said bio-sensor further senses the host genomic value, the host proteomic value, and the host metabolomic value associated with the GPCR condition using semiconductor nanocrystal or quantum-dot device as detectable label or probe by linking or bonding to one or more affinity molecules of a detectable substance in an analyte, whereupon such nanocrystal probe in response to a first energy associated with a presence of detectable substance within material bonded to the probe, excites the nanocrystal in the probe and causes the probe to provide a second energy or generate or fluoresce a distinct wavelength signal indicating the presence.

2. Apparatus of claim 1 wherein one or more bioinformatic value comparison is automated via rule-based Bayesian, neural network, fuzzy logic or expert system.

3. Apparatus of claim 1 wherein said bio-sensor comprises a semiconductor nanocrystal or quantum dot device for sensing the host metabolomic value for small organic molecules, and metabolic response thereof.